Holen Sie sich die Stockscreener-App
33.54
0.42%
-0.14
Schlusskurs vom Vortag:
$33.68
Offen:
$33.99
24-Stunden-Volumen:
631.85K
Relative Volume:
1.27
Marktkapitalisierung:
$1.09B
Einnahmen:
$796.33M
Nettoeinkommen (Verlust:
$74.95M
KGV:
16.42
EPS:
2.0427
Netto-Cashflow:
$329.83M
1W Leistung:
-2.33%
1M Leistung:
-0.33%
6M Leistung:
-32.01%
1J Leistung:
+13.31%
1-Tages-Spanne:
$33.01
$34.27
1-Wochen-Bereich:
$31.69
$35.21
52-Wochen-Spanne:
$29.19
$50.79
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Firmenname
Collegium Pharmaceutical Inc
Sektor
Telefon
781-713-3699
Adresse
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
33.54 | 1.09B | 796.33M | 74.95M | 329.83M | 2.0427 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-01-10 | Hochstufung | Needham | Hold → Buy |
| 2024-07-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-05-10 | Herabstufung | Needham | Buy → Hold |
| 2024-05-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-08-25 | Bestätigt | Needham | Buy |
| 2023-05-02 | Fortgesetzt | Jefferies | Buy |
| 2022-08-08 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-14 | Eingeleitet | BWS Financial | Sell |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-19 | Fortgesetzt | Jefferies | Buy |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2019-04-12 | Fortgesetzt | Janney | Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2018-02-07 | Bestätigt | Needham | Buy |
| 2017-12-05 | Bestätigt | Needham | Buy |
| 2017-09-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-09-13 | Eingeleitet | Gabelli & Co | Buy |
| 2015-06-01 | Eingeleitet | Jefferies | Buy |
| 2015-06-01 | Eingeleitet | Needham | Buy |
| 2015-06-01 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Collegium Pharmaceutical Inc Aktie (COLL) Neueste Nachrichten
Collegium Pharmaceutical Inc (COLL) Institutional Confidence - TradingKey
Collegium Pharmaceutical Inc (COLL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Collegium Pharmaceutical Inc (COLL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Collegium Pharmaceutical Inc - TradingKey
Collegium Pharmaceutical Inc (COLL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Collegium Pharmaceutical Inc (COLL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Collegium Pharmaceutical Inc (COLL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Trading Systems Reacting to (COLL) Volatility - Stock Traders Daily
COLL Stock Price, Quote & Chart - ChartMill
Collegium Pharmaceutical Inc. Q1 2026 Earnings: EPS Surges Past Estimates on Strong Operational Execution - newsline.com
COLLEGIUM PHARMACEUTICAL (COLL) director exercises options, now holds 112,483 shares - Stock Titan
Collegium Pharmaceutical grants 50,305 RSUs to 34 new hires as inducement under Nasdaq rules. - Pluang
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
2 Reasons to Sell COLL and 1 Stock to Buy Instead - Yahoo Finance
Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness - Yahoo Finance
Collegium Pharmaceutical Gains Attention on Strong ADHD Portfolio and Q1 2026 BeatEPS Revision Trend - thelegaladvocate.com
This Insider Has Just Sold Shares In Collegium Pharmaceutical - 富途牛牛
Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio - Insider Monkey
Collegium to Participate in 2026 Jefferies Global Healthcare Conference - The Manila Times
Investors can stream Collegium's Jefferies healthcare fireside chat live - Stock Titan
Collegium Pharmaceutical Acquires ADHD Drug AZSTARYS® from Corium Therapeutics - geneonline.com
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1 - TradingView
(COLL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
How Strong Q1 Earnings and Executive Departures At Collegium Pharmaceutical (COLL) Have Changed Its Investment Story - simplywall.st
Collegium Pharmaceutical stock (US19459E1029): insider trade draws attention as Wall Street sees ups - AD HOC NEWS
Collegium (NASDAQ: COLL) director sells 20 shares, holds 83,952 - Stock Titan
Collegium Pharma Leans on ADHD to Drive Growth - TipRanks
Collegium pharmaceutical director sells $142k in shares By Investing.com - Investing.com Australia
Collegium pharmaceutical director sells $142k in shares - Investing.com India
Director Nancy Lurker awarded 8,741 RSUs at Collegium (COLL) - Stock Titan
Director Carlos V. Paya granted 8,741 RSUs at COLLEGIUM (NASDAQ: COLL) - Stock Titan
Collegium (COLL) director sells shares, exercises options and receives RSU grant - Stock Titan
Director at Collegium (COLL) awarded 17,482 restricted stock units - Stock Titan
Director at Collegium (NASDAQ: COLL) receives 8,741 RSUs in equity award - Stock Titan
Director at Collegium (NASDAQ: COLL) awarded 8,741 RSUs in equity grant - Stock Titan
COLL (NASDAQ) Form 144 shows 4,127-share sale and 30-share resale notice - Stock Titan
Collegium Pharmaceutical (COLL) director Donovan Glancy files initial Form 3 - Stock Titan
Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Have Collegium Pharmaceutical Insiders Been Selling Stock? - simplywall.st
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know - Yahoo Finance
Collegium Pharmaceutical stock (US19459E1029): opioid-pain specialist in focus after Q1 2026 earning - AD HOC NEWS
Collegium Shareholders Back Board, Pay and Auditor Choices - TipRanks
Collegium (NASDAQ: COLL) shareholders back board, pay and auditor at 2026 meeting - Stock Titan
Collegium Pharmaceutical (COLL) director sells 4,500 shares in market trade - Stock Titan
Janus Henderson (COLL) reports 1.83M-share, 5.8% holding in PHARMACEUTICAL, INC. - Stock Titan
[SCHEDULE 13G/A] COLLEGIUM PHARMACEUTICAL, INC Amended Passive Investment Disclosure - Stock Titan
[144] COLLEGIUM PHARMACEUTICAL, INC SEC Filing - Stock Titan
Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality - 富途牛牛
Truist Financial Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating - Moomoo
Renaissance files 4.53% holding in PHARMACEUTICAL, INC (COLL) - Stock Titan
Barclays Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Finanzdaten der Collegium Pharmaceutical Inc-Aktie (COLL)
Umsatz
Nettogewinn
Free Cashflow
ENV
11.23%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):